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Abstract: Choroidal neovascularization (CNV) is a pathological process in which aberrant blood
vessels invade the subretinal space of the mammalian eye. It is a characteristic feature of the prevalent
neovascular age-related macular degeneration (nAMD). Circulating microRNAs (cmiRNAs) are
regarded as potentially valuable biomarkers for various age-related diseases, including nAMD. Here,
we investigated cmiRNA expression in an established laser-induced CNV mouse model. Upon CNV
induction in C57Bl/6 mice, blood-derived cmiRNAs were initially determined globally by RNA
next generation sequencing, and the most strongly dysregulated cmiRNAs were independently
replicated by quantitative reverse transcription PCR (RT-qPCR) in blood, retinal, and retinal pigment
epithelium (RPE)/choroidal tissue. Our findings suggest that two miRNAs, mmu-mir-486a-5p and
mmur-mir-92a-3p, are consistently dysregulated during CNV formation. Furthermore, in functional
in vitro assays, a significant impact of mmu-mir-486a-5p and mmu-mir-92a-3p on murine microglial
cell viability was observed, while mmu-mir-92a-3p also showed an impact on microglial mobility.
Taken together, we report a robust dysregulation of two miRNAs in blood and RPE/choroid after
laser-induced initiation of CNV lesions in mice, highlighting their potential role in pathology and
eventual therapy of CNV-associated complications.
Keywords: cmiRNA regulation; age-related macular degeneration; laser-induced choroidal
neovascularization; biomarker
1. Introduction
The blood retinal barrier separates the neural retina from the circulatory system. It is comprised
of an inner barrier, formed by tight junctions between adjacent retinal endothelial cells, and an outer
network of tight junctions between adjacent retinal pigment epithelium (RPE) cells. The two barriers
constitute a sophisticated system to allow the diffusion of very small molecules such as oxygen and
glucose to the neural retina, while inhibiting the passive flux of larger particles. Pathological processes,
such as choroidal neovascularization (CNV), disrupt this barrier with detrimental consequences for
retinal homeostasis. Prior to CNV, the retina responds to hypoxic stress by upregulating the expression
of vascular endothelial growth factor (VEGF), which in turn results in the ingrowth of new blood
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vessels from the choriocapillaris [1–3]. Such fragile vessels invade the RPE monolayer, leaking serous
fluid, lipids, and blood into the neural retina. Consequently, CNV is associated with a number of
pathological conditions, including myopia and osteogenesis imperfecta, but most commonly occurs in
the neovascular late-stage form of age-related macular degeneration (nAMD) [4–6].
AMD is a complex disease of the central retina, and is the third leading cause of blindness
worldwide owing to atrophic or neovascular manifestations [7]. In nAMD, the formation of CNV
lesions is initially accompanied by an inflammatory response, which eventually results in the formation
of scar tissue [8,9]. While in early AMD, the initial decrease in visual acuity is slow and often remains
unnoticed, the onset of CNV is consistently associated with rapid vision loss [10]. Understanding
the etiology of AMD and its late complications has challenged retinal researchers for decades, while
in more recent years, it is commonly agreed upon that genetic predisposition and environmental
influences are the main risk factors driving AMD pathology [11–13]. Recently, evidence has emerged
that suggests that epigenetic mechanisms, such as microRNA (miRNA) modulated gene expression,
are likely to be involved in early disease processes [14,15]. MiRNAs are short, non-coding RNAs, which
bind to and degrade mRNA transcripts, thereby modifying gene expression. Although initially thought
to be confined to intracellular modes of action, miRNAs were demonstrated by Chim and colleagues to
be present extracellularly as so-called circulating miRNAs (cmiRNAs) in blood plasma [16]. Since then,
cmiRNAs have been recognized as an exciting new avenue of research for many pathologies, mainly
owing to their potential in diagnostic and therapeutic applications. Multiple groups have previously
investigated differentially expressed cmiRNA in nAMD patients, but so far, there is no consensus about
which cmiRNAs are truly dysregulated [17].
The aim of this study was first to provide clarity in the field of cmiRNA dysregulation in nAMD
patients, by reviewing and summarizing previous publications. Further, we intend to identify robustly
dysregulated cmiRNAs in a laser-induced CNV mouse model. This model involves the use of controlled
argon laser irradiation to locally puncture Bruch’s membrane [18,19]. After treatment, the mice develop
a characteristic- and time-dependent inflammatory and angiogenic ocular response [18]. Initially, the
mice develop an immunological reaction during which time inflammatory cells such as neutrophils
and macrophages invade the choroid and resident retinal microglia are activated [20]. In contrast to
this early reaction, the onset of angiogenesis peaks around day 7, but is still relatively prominent at
day 14 after treatment [18].
Here, we analyzed global alterations in murine cmiRNA expression at various time points after
laser treatment. The most strongly dysregulated cmiRNAs were then independently quantified by
real-time reverse transcription PCR (RT-qPCR) in blood, retinal, and RPE/choroid tissue. We identified
two reproducibly dysregulated cmiRNAs and performed a series of in vitro assays in murine microglial
and endothelial cells, characterizing functional effects of these miRNAs on cell viability, migration,
vascularization, and immune regulation.
2. Results
2.1. Literature Search for cmiRNA Dysregulation in nAMD Patients
So far, several studies have investigated cmiRNA dysregulation in nAMD patients, but they exhibit
a high variability of the identified cmiRNAs. To enable a comprehensive overview of dysregulated
cmiRNAs in nAMD, we performed a literature search, and compiled the dysregulated cmiRNAs that
were identified by each study (Figure 1; Supplementary Table S1). Only studies that investigated
cmiRNAs in serum, plasma, or whole blood of nAMD patients were included. Six studies fulfill
these criteria, and they identified in total 42 different cmiRNAs to be related to nAMD [21–26].
Only two cmiRNAs were identified in two independent studies, which were both upregulated
(hsa-mir-146a and hsa-mir-27a) [23–25]. In contrast, two additional cmiRNAs were also identified
in two independent studies, but in opposite directions. One study showed that hsa-mir-34a and
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hsa-mir-126 were upregulated in their patient cohort, while another study showed that these cmiRNAs
were downregulated in their patient cohort [24,26].
Of special note, a single study detected all four of the previously mentioned cmiRNAs [25].
However, the results of this study should be regarded with caution, as they may not adequately identify
the mature miRNA they investigated. An important step in miRNA biogenesis is the processing of the
pre-miRNA hairpin structure to a mature miRNA duplex [27–29]. This duplex results in two functional
miRNA strands, and the directionality of these strands is used to differentiate between them. The 5′
end of the hairpin results in the 5p strand, while the 3′ end results in the 3p strand. The proportion
between the functional 5p and 3p strands varies. In some cases, both strands are functional, but it can
also be skewed towards one strand or the other [30,31]. Although most publications that investigated
cmiRNA expression in nAMD patients documented the strand they detected, this one publication
mentioned above did not [25]. Consequently, one cannot be certain about the true nature of the
respective cmiRNAs in this study.
Importantly, the vast majority of cmiRNAs (38/42) differentially expressed in nAMD patients in
one study have never been replicated in an independent study. Although some variability is to be
expected, the inconstancy of these results prohibits the identification of distinct cmiRNAs that show a
robust differential expression in nAMD patients.
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cmiRNAs are marked with a dash. The prefix of each cmiRNA is hsa-mir-, except for hsa-let-7c. Two 
cmiRNAs were upregulated in patients in two studies, hsa-mir-146a-5p and hsa-mir-27a-3p 
(highlighted in green). In contrast, two other cmiRNAs were upregulated in one study, and 
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Figure 1. Circulating microRNA (cmiRNA) dysregulation in neovascular age-related macular
degeneration (nAMD) patients summarized from literature data. Each circle represents one publication,
which investigated cmiRNAs in hu an nAMD patients. The size of ach circle repr s nts the number
of participants included in the study (small circle: <49 parti ipants, medium circle: 50–149 participants,
large circle: >150 participants). The year the study was published is denoted inside each circle. The
cmiRNAs identified by each study are listed around the circle, and downregulated cmiRNAs are
marked with a dash. The prefix of each cmiRNA is hsa-mir-, except for hsa-let-7c. Two cmiRNAs
were upregulated in patients in two studies, hsa-mir-146a-5p and hsa-mir-27a-3p (highlighted in
green). In contrast, two other cmiRNAs were upregulated in one study, and d wnregulated in another,
hsa-mir-34a an hsa-m r-126 (highlighted in red). Of note, one publication did not indicate which
mature strand (3p or 5p) was investigated. In total, 38 of the 42 (90%) cmiRNAs differentially regulated
in nAMD patients have not been replicated in independent studies.
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2.2. CmiRNA Expression after Laser-Induced CNV Formation in C57Bl/6 Mice
CmiRNAs were determined in mice after laser-induced CNV formation in a discovery and
an independent replication study. Initially, six mice were treated with an argon laser to induce
CNV on day 1. Blood samples were drawn on days 0 (baseline), 3, and 14 (Figure 2A). On day 14,
CNV was confirmed via angiography and spectral domain optical coherence tomography (SD-OCT).
In the discovery study, cmiRNA expression profiles were analyzed via global RNA sequencing 3
and 14 days after laser treatment, respectively. CmiRNA expression profiles from day 0 (one day
prior to laser treatment) and 5 untreated mice (age-matched with day 14 samples) were used as
controls. The cmiRNA expression profiles were compared between all groups, demonstrating that the
expression of most cmiRNAs remained stable upon laser treatment (Figure 2B; Supplementary Table
S2). To detect cmiRNAs dysregulated after laser treatment, we initially compared cmiRNA expression
on day 0 (baseline) with day 3 and day 14 after treatment, as well as day 3 and day 14 with each other.
By placing thresholds at p-value < 0.05 and absolute slope > 0.4, cmiRNAs were selected from each
group for further analysis (Supplementary Table S3). The expression of the selected cmiRNAs was then
correlated in a second comparison with the data from the untreated control animals. Here, we assumed
that cmiRNA expressions at day 0 baseline and untreated control mice are comparable. To this end,
we tested if any of the potential candidates revealed an altered expression between these two control
groups, and applied the same criteria as in the initial comparison (p-value < 0.05 and absolute slope >
0.4). This excluded cmiRNA mmu-mir-326-3p from further analysis (Supplementary Table S4). Then,
the expression of the remaining candidates in the untreated control mice was analyzed in comparison
with the expression at day 3 or day 14. Only cmiRNAs that replicated the slope direction and an
absolute slope > 0.2 were considered for the replication study (Figure 2C, Supplementary Table S4).
Nine remaining cmiRNAs were subjected to an independent replication by RT-qPCR in two
independent batches of animals, including 6 and 12 mice treated with an argon laser on day 1, and a
blood withdrawal scheme on days 0, 3, 7, and 14 (Figure 2A). Note that the data set in the replication
study was enriched for samples from day 7, to more accurately measure cmiRNA expression over time.
Seven of the cmiRNAs showed an expression slope in the same direction as in the discovery study
(Supplementary Table S5). Three cmiRNAs, mmu-mir-486a-5p, mmu-mir-92a-3p, and mmu-mir-155-5p,
were significantly regulated at one or several time points after laser treatment (p-value < 0.05, Figure 2D,
Supplementary Figure S1).
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Figure 2. CmiRNA regulation after laser-induced choroidal neovascularization (CNV) in a discovery
and a replication study. (A) Mice received laser treatment on day 1, and blood was drawn on day
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formation was confirmed via angiography and SD-OCT. (B) Comparison of cmiRNA profiles of untreated,
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day 3, or day 14 samples with day 0 samples. This analysis demonstrates an overall stable cmiRNA
expression after laser treatment. (C) On the x-axis, the slopes of candidate cmiRNA expression on day
0 compared to day 3 or day 14 are shown. The slope of these cmiRNAs are given on the y-axis, when
analyzed in comparison with untreated control mice. The dotted lines represent the slope threshold of
an absolute slope > 0.2. Candidates in between the dotted lines were excluded from further analysis.
(D) The relative expression values of three significantly dysregulated cmiRNAs in the discovery study
and replication study are shown. For the independent replication study using quantitative reverse
transcription PCR (RT-qPCR), two additional batches of mice were treated with an argon laser, including
6 and 12 mice, respectively. Shown are relative expression values normalized to the median expression
on day 0 for the three cmiRNAs. All three cmiRNAs were differentially regulated at one or several time
points of measurement (day 3, 7, and 14) in comparison with day 0. * p-value < 0.05 (linear regression
model). SD-OCT, spectral domain optical coherence tomography; NGS, next generation sequencing.
2.3. MiRNA Expression in Retinal and RPE/Choroidal Tissue
The expression of two significantly and robustly dysregulated cmiRNAs (mmu-mir-486a-5p and
mmu-mir-92a-3p) was further investigated in ocular tissues by RT-qPCR. Mmu-mir-155-5p showed
strong expression fluctuations and a small effect size (slope < 0.06) in blood and was not further
investigated. For this analysis, 36 mice were treated with argon laser on day 1, and retinal and
RPE/choroidal tissues were extracted from 12 mice, on day 3, day 7, and day 14 (Figure 3A), respectively.
MiRNA expression was compared to those from the 12 untreated control mice. In retinal tissue, neither
mmu-mir-486a-5p nor mmu-mir-92a-3p was significantly dysregulated after laser treatment at any
time point (Figure 3B, , Supplementary Table S6). In the RPE/choroidal tissue, the two miRNAs
showed a statistically significant upregulation after laser treatment for at least two time points
each (Q-value < 0.05, Figure 3B, , Supplementary Table S6). For mmu-mir-486a-5p, the strongest
dysregulation was observed on day 3 (slope = 0.408 (0.188–0.628)). In contrast, the expression of
mmu-mir-92a-3p increased steadily over time (slope on day 14 = 0.466 (0.084–0.848)).
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untreated control mice. * Q-value < 0.05 (linear regression model, false discovery rate (FDR) corrected).
2.4. Functional Characterization of miRNAs in Murine Endothelial and Microglial Cells
A series of exp riments were performed to inv stigate the functional effects of the two
candidate miRNAs in murine microglial (BV-2) and murine endothelial cells (C166). By RT-qPCR,
we initially verified that all miRNAs were overexpressed successfully in the two model cell lines
(Figure 4a, Supplementary Table S7). Although miRNAs mmu-mir-92a-3p and mmu-mir-486a-5p
were overexpressed, we observed fluctuations in the expression profiles, ranging from 9.7-fold for
mmu-mir-92a-3p in BV-2 to 147.6-fold for mmu-mir-486a-5p also in BV-2. These effects may be the
result of a variable endogenous expression of the respective miRNAs. Of note, the control miRNA
cel-mir-39-3p (which has no homologue in the ouse) showed the strongest overexpression of around
2500-fold in both cell lines used (Figure 4A).
Overexpression of mmu-mir-92a-3p and mmu-mir-486a-5p in the murine microglial cell line BV-2
resulted in a significant reduction of cell viability, in comparison with cells transfected with control
miRNA cel-mir-39-3p (Figure 4B, Supplementary Table S8). Furthermore, murine microglial cells
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transfected with mmu-mir-92a-3p also showed a reduced migration in a scratch assay (Figure 4C,
Supplementary Table S8). To measure the response of murine microglial cells to immunological stimuli,
cells were stressed with lipopolysaccharide (LPS) and nitric oxide (NO) levels were quantified [32].
However, no significant response of miRNA overexpression in murine microglia was observed
upon LPS stress (Supplementary Table S8). We also did not observe a significant effect of miRNA
overexpression in murine endothelial cells C166 on network length in a tube formation assay, on cell
migration in a scratch assay, or on cell viability (Supplementary Table S8).
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interest, which were corrected using FDR).
3. Discussion
Laser induction of CNV lesions in the mouse eye is a commonly used in vivo model to induce
inflammation and angiogenesis—two hallmarks of nAMD [18,19]. As far as we could find out, this
model has never been used in the context of miRNA regulation. We used laser treatment to induce the
formation of CNV lesions in mice, and identified three cmiRNAs that were reproducibly dysregulated.
We further demonstrated that two robustly dysregulated cmiRNAs also display an altered expression
in RPE/choroidal tissue after laser treatment. Interestingly, the observed effects for both miRNAs in
ocular tissue are in the opposite direction when compared with blood.
Several studies have investigated serum and plasma cmiRNA levels in nAMD patients [21–26],
but the findings in-between studies appear difficult to reproduce [17]. This emphasizes the need for
alternative approaches to detect robustly dysregulated cmiRNAs in CNV. While miRNAs are known
to maintain cellular homeostasis by buffering against cellular and organismal stress [33], many factors
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seem to influence fluctuations in cmiRNA expression. We designed our experiments to minimize these
effects, and aimed to identify cmiRNAs that were dysregulated solely owing to the laser treatment.
We analyzed cmiRNA expression profiles in several steps, with less strict p-value thresholds initially to
focus on the reproducibility of expression trends. Therefore, candidate cmiRNAs had to pass several
stages of analysis, including comparisons with two control groups (day 0 before treatment and untreated
mice), and an independent replication study with two independent batches of animals. We did not
perform correction for multiple testing at these early steps of analysis, instead, candidate cmiRNAs
had to show consistent effect sizes and pass several p-value thresholds. Consequently, this approach
identified three highly valid and reproducibly dysregulated cmiRNAs, namely, mmu-mir-486a-5p,
mmu-mir-92a-3p, and mmu-mir-155-5p.
An interesting cmiRNA detected in our analysis initially, but not followed through the study is
mmu-mir-155-5p, which was upregulated in blood on day 14 with a 1.8-fold increase. This is one
of the strongest expression differences we observed in our analysis, compared with the other two
significantly differentially expressed cmiRNAs (strongest fold change of mmu-mir-486a-5p = 0.62,
mmu-mir-92a-3p = 0.85). In contrast, the regression model showed a rather moderate effect size (slope)
for mmu-mir-155-5p, in comparison with the other cmiRNAs. By definition, “fold change” refers
to differences between the mean expression values of two groups. In vivo models are complex, and
include many sources of variability and confounding effects. We thus adjusted for known confounders
by applying regression models, and chose to set thresholds using the output of the regression model
(slope and p-value). Besides this statistical issue, differential expression of mmu-mir-155-5p was
reported for several diseases, including immune response to infection [34,35], Alzheimer’s disease [36],
multiple sclerosis [37], and cancer [38–40]. On the basis of the fluctuation of values we observed, and
the known associations with other diseases, we questioned the benefit of mir-155-5p as a specific and
reliable biomarker for nAMD.
Mmu-mir-92a-3p and mmu-miR-486a-5p were significantly dysregulated in our study. In blood,
both cmiRNAs were downregulated on day 3, and in RPE/choroid, they were upregulated inter alia on
day 3. Thus, in our study, these two miRNAs are regulated in different directions in different tissues,
although at the same time point since setting the retinal insult. These results corroborate previous
findings, which support dynamic differences in intercellular miRNA expression profiles. A recent
study investigated cell-type specific patterns of miRNA expression, and revealed profound differences,
even in closely related cell types [41]. Furthermore, another study that co-sequenced single cell miRNA
and mRNA theorized that intercellular mRNA heterogenity could be caused by miRNA heteregenity,
and thereby help to explain non-genetic cell to cell variability [42]. Even more interesting is the concept
that the function of miRNA can vary based on the cell type. In a previous study, overexpression of
mir-92a resulted in increased proliferation in a breast cancer cell line and an acute promyeloic leukemia
cell line, but increased apoptosis in a T cell leukemia cell line [43]. The differences in miRNA expression
as defined in our study may not be artificial findings, but instead could reflect functional characteristics
and so far only little is understood in the context of neovascular injury of the retina.
In our analysis, mmu-mir-486a-5p and mmu-mir-92a-3p were downregulated in blood at day
3 after treatment, which is characterized by an immune reaction owing to laser treatment [18,20].
At this time point, neutrophils and macrophages invade the choroid and resident retinal microglia are
activated [20]. To investigate the effect of these two miRNAs in vitro, we overexpressed each miRNA
in murine microglial cells, known as the immunological watchdogs of the retina [44]. We observed
a reduced viability of microglial cells for each miRNA, and a reduced microglial migration rate for
mmu-mir-92a-3p. We theorize that downregulation of mmu-mir-486a-5p and mmu-mir-92a-3p leads
to an enhanced microglia function, and thus could be correlated to the observed immune reaction
at this time point. An involvement of miRNAs in the immune response is well documented [45,46].
Specifically, a landmark study showed that mir-92a was involved in cell–cell communication of T and B
lymphocytes [47], key mediators of the bodies’ humoral immune response. Overall, we postulate that
expression changes observed in blood are part of the murine immune reaction after laser treatment.
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In contrast to blood, mmu-mir-486a-5p and mmu-mir-92a-3p were upregulated in RPE/choroid
after laser treatment. A previous study demonstrated that, in the human RPE cell line ARPE-19, the
human homologue to mmu-mir-486a-5p, hsa-mir-486-5p, was upregulated upon oxidative stress [48].
This is an interesting finding because oxidative stress is known to be critical in AMD pathogenesis [49].
Similarly, hsa-mir-92a was upregulated in human umbilical vein endothelial cells after oxidative
stress induction. In our study, both miRNAs were upregulated in RPE and choroidal tissue, whose
main components are RPE and endothelial cells. Possibly, upregulation of mmu-mir-486a-5p and
mmu-mir-92a-3p is a cell-type specific effect of RPE and endothelial cells upon a laser-induced stress
reaction, comparable to oxidative stress.
Interestingly, upregulation of mmu-mir-92a-3p in RPE/choroidal tissue increased over time. In the
laser-induced CNV model, an angiogenic reaction follows the immune reaction. The neovascular
surface area peaks at day 7, and is still relatively prominent at day 14 [18]. The increased expression of
mmu-mir-92a-3p in RPE/choroidal tissue during these time points could indicate an involvement of
this miRNA in the ocular angiogenic reaction. Previously, the impact of this miRNA on angiogenesis
was studied, although with contradicting results [50–53]. So far, there is no consensus on whether
mir-92a is a positive or negative regulator of angiogenesis. It was argued that the inconsistent results
are owing to small variations in the experimental set-up [51]. This could explain why we failed to
identify an effect of mmu-mir-92a-3p in the tube formation assay in murine endothelial cells. Still,
mmu-mir-92a-3p may have a consequence on angiogenesis in our in vivo model, even though there
was no recordable effect in the in vitro assay.
Taken together, we found a robust differential regulation of three cmiRNAs in blood of laser-treated
mice established to represent a model of nAMD. Two of these cmiRNAs, mmu-mir-486a-5p and
mmu-mir-92a-3p, were followed up in further experiments. Both were downregulated in blood and
upregulated in RPE/choroidal tissue after laser treatment, which could indicate cell-type specific
regulation and function. In blood, both miRNAs are likely involved in an immune reaction, while in
RPE/choroidal tissue, a stress reaction may be comparable to an oxidative stress reaction.
4. Materials and Methods
4.1. Ethical Statement on Animal Studies
This animal study conformed to the Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research, and was approved by
the government of North Rhine-Westphalia (ID: 84-02.04.2015.A413).
4.2. Literture Analysis of Differentially Expressed cmiRNAs in nAMD Patients
A literature search was performed in Pubmed in March 2020. Studies that investigated cmiRNA
dysregulation in nAMD patients were compiled. In total, six studies met these criteria [21–26].
Studies that investigated intracellular cmiRNAs [54,55], cmiRNAs in exosomes [56], a combination of
nAMD and geographic atrophy AMD patients [57,58], and a combination of nAMD and congenital
hemochromatosis patients [59] were excluded.
4.3. Induction of CNV Lesions in the Mouse Model
CNV was induced in mice as previously described, with minor modifications [60]. In this study,
female drug and test naїve C57Bl/6J mice were used. Mice were 78 days old, with the exception of the
tissue studies, which were 56 days old. Mice from the tissue studies’ harvest on day 14 also served as
second batch for the blood replication study, and were 56 days old. The mice were anesthetized with
Rompun (6 mg/kg) and Ketavet (100 mg/kg), and pupils were dilated with drops of Phenylephrine
HCl (0.25%)–Tropicamide (0.05%). For the laser procedure, 2% Methocel (OmniVision, Puchheim,
Germany) was applied topically before adding a microscopy cover slip to enable precise laser induction.
The fundus was visualized with an imaging camera, and laser photocoagulation was induced using
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the image-guided laser system. Six laser burns at an equal distance from the optic nerve were induced
in each eye by a green Argon laser pulse with a wavelength of 532 nm, a fixed diameter of 50 µm,
duration of 100 ms, and power levels of 150 mW. Eyes that developed vitreous bleeding, cataract, or
keratopathy were excluded from the analysis.
Mice were then placed on a pre-warmed warming plate at 35 ◦C, until they regained consciousness.
SD-OCT was performed using the image-guided OCT system as previously described [17].
4.4. Blood and Tissue Sample Preparation and cmiRNA Isolation
For the discovery study, six mice were treated with an argon laser on day 1, and blood was drawn
on day 0 (one day before treatment), 3, and 14. Blood was drawn once from five untreated mice
age-matched to day 14 laser-treated samples. For the replication study, two independent batches
of mice were treated with argon laser, and blood was drawn on day 0, 3, 7, and 14. The first batch
consists of six mice and the second batch of 12 mice. Retinal and RPE/choroidal tissue from day 14 was
taken from the same mice that were used for blood collection in batch 2. Tissue was extracted from 12
additional laser treated mice per time point on day 3 and 7. Ocular miRNA expression in laser treated
mice was compared to the expression in the 12 untreated mice.
For the blood samples, ~40 µL of peripheral venous blood was drawn via the facial vein and mixed
with 120 µL PAXgene Blood RNA tube stabilizing solution (PreAnalytiX GmbH, Hombrechtikon,
Switzerland). Prior to RNA isolation, samples were centrifuged for 10 min at 2800× g at 4 ◦C, and the
supernatant (~150 µL) was collected and used for RNA isolation. For the tissue samples, the retina and
RPE/choroid was extracted and snap frozen in liquid nitrogen. Prior to RNA isolation, tissue samples
were homogenized in 300 µL lysis buffer with pestles, and further disintegrated by passing them
through 18 G, 20 G, and 23 G needles. RNA isolation from blood and tissue was performed according to
the procedures for organic extraction and total RNA isolation from the mirVANA microRNA isolation
kit (Ambion, Waltham, MA, USA) as previously described [22,61], with the following modifications.
The centrifugation step during the phenol/chloroform extraction was performed for 30 min at 4 ◦C.
Finally, RNA was eluted in 50 µL of nuclease-free water (Ambion, Waltham, MA, USA).
4.5. Sequencing of cmiRNAs and Data Analysis (Discovery Study)
cDNA libraries were constructed from blood samples using the NEXTflex™ Small RNA-Seq Kit
v3 (Bioo Scientific, Austin, TX, USA), according to the manufacturer’s instructions. The cDNA libraries
were multiplexed using the multiplex primers included in the kit. The resulting cDNA libraries
were purified using AMPure beads (Beckman Coulter, Brea, CA, USA), and their concentration and
size distribution were determined on an Agilent BioAnalyzer DNA high-sensitivity Chip (Agilent
Technologies, Santa Clara, CA, USA). Up to 12 libraries were pooled at equimolar concentrations.
Sequencing was performed on a MiSeq Desktop Sequencer using the MiSeq Reagent Kit v3 with
150 cycles (Illumina, San Diego, CA, USA). As most of the reads are expected to be from very
few cmiRNAs (similar to human studies [22]), we used a conservative 20% PhiX spike-in, to avoid
sequencing problems associated with low diversity libraries.
The obtained sequencing data were analyzed with the mirDEEP2 package [62]. Briefly, all reads
were mapped to the murine genome (mm10) using BowTie2 [63]. Reads that failed to align were
excluded. Remaining reads were mapped to the pre-miRNA and miRNA sequences obtained from
mirbase.org (Release 21 June 2014) and quantified. Using the statistical software R [64], the data
were normalized using a trimmed mean of M-values (TMM) algorithm implemented in the edgeR
package [65], and transformed with the binary logarithm. In order to account for the presence of batches
in the data occurring through independent sequencing runs, we employed an empirical Bayesian batch
effect correction algorithm known as ComBat [66].
For the analysis of cmiRNAs that were assayed over several time points, we used linear mixed
effects model implemented in the nlme package [67]. CmiRNAs were considered to be potential
candidates if the p-value was below 0.05 and the absolute slope was above 0.4. For the comparison of
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the two control groups (day 0 before laser treatment, and untreated control mice), a Firth’s bias-reduced
logistic regression model implemented in the logistf package [68] was used. CmiRNAs with a p-value
below 0.05 and an absolute slope above 0.4 in the comparison of day 0 mice with untreated mice were
excluded from further analysis. Candidates were validated in a comparison of treated and untreated
control mice using linear fixed effects models implemented in R. Candidates were considered to be
validated if the slope indicated the same direction as in the comparison with day 0 control group, and
only candidates with an absolute slope above 0.2 were retained.
4.6. RT-qPCR and Data Analysis (cmiRNA Replication Study and miRNA Expression in Tissue)
MiRNA reverse transcription followed by RT-qPCR was performed according to Hurteau et
al. [69]. Briefly, 50 ng of purified cmiRNA solution were modified by E. coli Poly (A) Polymerase I
(E-PAP) by the addition of a polyA tail (Ambion, Waltham, MA, USA). Reverse transcription was
performed with Superscript III reverse transcriptase (Invitrogen, Waltham, MA, USA) and a Universal
RT oligonucleotide primer, which contains a polyT stretch of DNA that binds to the newly synthesized
polyA tail (Supplementary Table S8). The RT solution was diluted 1:40, except for samples that had
previously been in long-term storage, which were diluted 1:10. Then, 4 µl diluted RT solution was
used per RT-qPCR reaction. Each RT-qPCR master mix was prepared according to the protocol of the
Power SYBR Green Master Mix (Applied Biosystems, Waltham, MA USA or Eurogentec, Cologne,
Germany), and run on an ABI Viia-7 (Applied Biosystems, Waltham, MA, USA) or a QuantStudio 5
(Applied Biosystems, Waltham, MA, USA). Each miRNA was assayed in triplicates (primer Sequences
are listed in Table S8). Primers that performed poorly (<50% RT-qPCR efficiency) were excluded from
further analysis. Primers for mature miRNA detection in retinal and RPE/choroidal tissue as well as
long-term stored blood samples were modified as reported elsewhere [70] (oligonucleotide primer
sequences are listed in Supplementary Table S9). We further excluded measurements with a standard
deviation greater than 0.4 Ct values in the triplicates. We used the TMM normalization algorithm
implemented in the edgeR package [65], in order to normalize the Ct-values according to the amount
of isolated RNA and reverse transcription efficiency. CmiRNA expression in blood was normalized to
the median of day 0 expression, and miRNA expression in tissues was normalized to the median of
untreated controls, to reduce potential batch effects. All batches were normalized separately.
For the RT-qPCR analysis of cmiRNAs, we used the linear mixed effects model implemented in the
nlme package [67]. Candidates were considered to be replicated if the slope was in the same direction
as in the discovery study, and the observed p-value was below 0.05. For the analysis of miRNAs in
retinal and RPE/choroidal tissue, we used a linear fixed effects models implemented in R. p-values
were adjusted per day and tissue, according to the FDR [71], implemented in the multtest package [72].
FDR values (Q-values) below 0.05 were considered significant.
4.7. Cell Culture and miRNA Mimic Transfection
C166 cells (murine endothelial yolk sac cells) (American Type Culture Collection, ATCC, Manassas,
VA, USA) were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) high glucose medium
containing 10% FCS (fetal calf serum). BV-2 cells (murine microglial cells) were grown in DMEM
high glucose medium containing 5% FCS and 195 µM β-Mercaptoethanol. Cells were transfected
with miRCURY LNA miRNA mimics (Qiagen, Hilden, Germany), and cel-mir-39-3p was used as
negative control (sequences are given in Supplementary Table S10). BV-2 cells were transfected
with Lipofectamine RNAiMax (Thermo Fisher Scientific, Waltham, MA, USA), according to the
manufacturer’s protocol. C166 were transfected with HiPerFect (Qiagen, Hilden, Germany), according
to the manufacturer’s protocol. Functional assays were performed 48 h after transfection.
4.8. RT-qPCR to Detect Overexpression
For quantification of miRNA overexpression, cells were seeded on a six well plate. RNA was
isolated 48 h after transfection, with the mirVANA microRNA isolation kit (Ambion, Waltham, MA,
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USA), as described previously, with minor modifications. Cells were harvested by adding 300 µL
of lysis buffer and cells were detached using cell scrapers. RT-qPCR was performed as described
above. Ct values greater than 0.4 were excluded, and overexpression was normalized to cel-miR-39-3p
transfected cells as control.
4.9. Tube Formation Assay
The tube formation assay was performed with the murine endothelial cell line C166 as described
elsewhere [73] with some modifications. Extracellular matrix Geltrex LDEV-Free Reduced Growth
Factor Basement Membrane Matrix (Thermo Fisher Scientific, Waltham, MA, USA) was used to
coat 96-well plates, with 37.5 µL per well. Plates were centrifuged 30 min at room temperature at
800–1000 rpm, and incubated afterwards for at least 15 min at 37 ◦C to allow gelling of the Geltrex.
Before seeding the C166 cells on 96-well plates, the plates were washed with 50 µL of DPBS (Dulbecco’s
phosphate buffered saline, Sigma Aldrich, St. Louis, MO, USA) per well. C166 cells were detached by
adding trypsin-ethylenediaminetetraacetic acid (EDTA) solution, and trypsin was stopped by adding
20% FCS in DPBS. Cells were centrifuged for 7 min at 1200 rpm, and the pellet was resuspended in 1/3
EGMPlus Endothelial Cell Growth Media-Plus with EGMPlus SingleQuots supplements (Lonza, Basel,
Switzerland) and 2/3 EGMPlus Endothelial Cell Growth Media-Plus without SingleQuots supplements.
Cells were counted with a CASY Cell Counter (OLS OMNI Life Science, Bremen, Germany) and
10,000 cells per well were seeded on the coated 96-well plate. Photos were taken after 5 h incubation at
37 ◦C, and the total length as well as the total segments length of the cellular network was determined
using the Angiogenesis Analyzer [74] for ImageJ.
4.10. Scratch Assay
Scratch assays were performed as described elsewhere [75] with some modifications. Twenty-four
hours after transfection, cells were seeded on 96-well plates. C166 cells were seeded on uncoated
plates, while BV-2 cells were seeded on plates coated with Poly-L-lysine hydrobromide (Sigma Aldrich,
St. Louis, MO, USA). After 24 h incubation at 37 ◦C, scratches were introduced into the confluent
monolayer of cells, using a WoundMaker (Essen BioScience, Ann Arbor, MI, USA). Photos were taken
0 h and 16 h after scratch induction. During this time, C166 cells were incubated at 37 ◦C with normal
cultivation medium and BV-2 cells were incubated with a reduced medium (DMEM high glucose
medium containing 1% FCS and 286 µM β-Mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA)).
Scratch areas were determined using ImageJ, and migration ability was defined as the percentage area
closed after 16 h incubation.
4.11. Viability
Twenty-four hours after transfection, cells were seeded on 96-well plates and incubated for 24 h.
Cell viability was measured using the Cell Counting Kit - 8 (Sigma Aldrich, St. Louis, MO, USA),
according to the manufacturer’s protocol. Absorbance at 455 nm was measured after 2 h incubation,
using a Spark microplate reader (Tecan, Männedorf, Switzerland).
4.12. NO Assay
Twenty-four hours after transfection, BV-2 cells were stressed with 200 ng/mL LPS from Escherichia
coli (Sigma Aldrich, St. Louis, MO, USA). After 20 h incubation at 37 ◦C, the NO concentration in the
supernatant was measured using the Griess Reagent System (Promega, Madison, WI, USA), according
to the manufacturer’s protocol. Absorbance at 540 nm was measured using a Spark microplate reader
(Tecan, Männedorf, Switzerland).
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4.13. Statistical Evaluation
For the statistical evaluation of the functional assays, a Kruskal–Wallis test was performed in R.
To correct for multiple comparisons, a Dunn’s multiple comparison test implemented in the Fisheries
Stock Analysis (FSA), R Package Version 0.8.25; [76] was performed. Uncorrected p-values for the
comparisons of interest were extracted, to avoid correction for comparisons that were not investigated.
Uncorrected p-values were corrected for multiple testing using the FDR [71] implemented in the multtest
package [72]. Each experimental assay was performed independently 4–7 times, with 4–8 technical
replicates each.
5. Conclusions
In this study, a laser-induced CNV mouse model was used to identify robustly dysregulated
miRNAs in blood and RPE/choroidal tissue. Each of these miRNAs, namely mmu-mir-486a-5p and
mmu-mir-92a-3p, has previously been linked to pathologic processes related to AMD pathogenesis.
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AMD age-related macular degeneration
ARPE-19 human retinal pigment epithelium cell line
BV-2 murine microglial cell line
C166 murine endothelial yolk sac cell line
cmiRNA circulating microRNA
CNV choroidal neovascularization
DPBS Dulbecco’s phosphate buffered saline
E-PAP E. coli Poly (A) Polymerase I
FCS fetal calf serum
FDR false discovery rate
HUVEC human umbilical vein endothelial cells
LPS lipopolysaccharide
miRNA microRNA
nAMD neovascular age-related macular degeneration
NGS next generation sequencing
NO nitric oxide
RPE retinal pigment epithelium cells
RT-qPCR quantitative reverse transcription PCR
SD-OCT spectral domain optical coherence tomography
SE standard error
TMM trimmed mean of M-values
VEGF vascular endothelial growth factor
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